Gan & Lee Pharmaceuticals. (SHA:603087)

China · Delayed Price · Currency is CNY

77.40

+2.55 (3.41%)

Sep 30, 2026, 3:00 PM CST

Market Cap	46.07B +1.3%
Revenue (ttm)	4.21B +10.8%
Net Income	1.15B +25.0%
EPS	1.94 +25.3%
Shares Out	595.20M
PE Ratio	39.90
Forward PE	28.77
Dividend	1.00 (1.29%)
Ex-Dividend Date	May 29, 2026

Volume	15,405,800
Open	75.03
Previous Close	74.85
Day's Range	74.56 - 79.20
52-Week Range	51.51 - 79.99
Beta	0.26
Analysts	Strong Buy
Price Target	83.00 (+7.24%)
Earnings Date	Oct 28, 2026

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insu... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 1998

Employees 5,309

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603087

Full Company Profile

Financial Performance

In 2025, SHA:603087's revenue was 4.05 billion, an increase of 33.06% compared to the previous year's 3.05 billion. Earnings were 1.14 billion, an increase of 86.05%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 603087 stock is "Strong Buy." The 12-month stock price target is ¥83.00, which is an increase of 7.24% from the latest price.

Price Target

¥83.00

(7.24% upside)

Analyst Consensus: Strong Buy

Stock Forecasts